All In Biotech

Drug Trial Radar · NCT02940860

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (FERWON-NEPHRO)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,538

Actual

Start

Nov 29, 2016

Primary completion

May 29, 2018

Study completion May 29, 2018

Sponsor

Lead sponsor
Pharmacosmos A/SIndustry
Sponsor type
Industry
First posted
Oct 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

Conditions

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia
  • Chronic Kidney Disease

Interventions

  • Iron isomaltoside/ferric derisomaltoseDrug

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

  • Iron sucroseDrug

    Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin (Hb) From Baseline to Week 8Time frame: Baseline to week 8
  2. Incidence of Protocol-defined Serious or Severe Hypersensitivity ReactionsTime frame: Baseline to week 8

Locations

141 sites in 1 country. Site status is shown where the registry gives one.

  • Pharmacosmos Investigational Site

    Huntsville, Alabama

  • Pharmacosmos Investigational Site

    Little Rock, Arkansas

  • Pharmacosmos Investigational Site

    Little Rock, Arkansas

  • Pharmacosmos Investigational Site

    Chula Vista, California

  • Pharmacosmos Investigational Site

    Fresno, California

  • Pharmacosmos Investigational Site

    Glendale, California

  • Pharmacosmos Investigational Site

    Glendale, California

  • Pharmacosmos Investigational Site

    Granada Hills, California

  • Pharmacosmos Investigational Site

    La Mesa, California

  • Pharmacosmos Investigational Site

    Los Angeles, California

  • Pharmacosmos Investigational Site

    Los Angeles, California

  • Pharmacosmos Investigational Site1

    Los Angeles, California

  • Pharmacosmos Investigational Site2

    Los Angeles, California

  • Pharmacosmos Investigational Site

    Los Angeles, California

  • Pharmacosmos Investigational Site

    Lynwood, California

  • Pharmacosmos Investigational Site

    Montebello, California

  • Pharmacosmos Investigational Site

    Northridge, California

  • Pharmacosmos Investigational Site

    Northridge, California

  • Pharmacosmos Investigational Site

    Porterville, California

  • Pharmacosmos Investigational Site

    Rialto, California

  • Pharmacosmos Investigational Site

    Riverside, California

  • Pharmacosmos Investigational Site

    Sacramento, California

  • Pharmacosmos Investigational Site

    San Dimas, California

  • Pharmacosmos Investigational Site

    San Francisco, California

  • Pharmacosmos Investigational Site

    Tarzana, California

  • Pharmacosmos Investigational Site

    Arvada, Colorado

  • Pharmacosmos Investigational Site

    Denver, Colorado

  • Pharmacosmos Investigational Site

    Westminster, Colorado

  • Pharmacosmos Investigational Site

    Middlebury, Connecticut

  • Pharmacosmos Investigational Site

    Plainville, Connecticut

  • Pharmacosmos Investigational Site

    Boynton Beach, Florida

  • Pharmacosmos Investigational Site

    Brandon, Florida

  • Pharmacosmos Investigational Site

    Coral Gables, Florida

  • Pharmacosmos Investigational Site

    Coral Springs, Florida

  • Pharmacosmos Investigational Site

    Doral, Florida

  • Pharmacosmos Investigational Site

    Fort Lauderdale, Florida

  • Pharmacosmos Investigational Site1

    Hialeah, Florida

  • Pharmacosmos Investigational Site2

    Hialeah, Florida

  • Pharmacosmos Investigational Site3

    Hialeah, Florida

  • Pharmacosmos Investigational Site

    Hollywood, Florida

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.